Interactions between HIV-1 protease, silver nanoparticles, and specific peptides

被引：14

作者：

Tsai, Chieh-Hsuan ^{[1
]}

Whiteley, Chris G. ^{[2
]}

Lee, Duu-Jong ^{[1
,3
,4
,5
]}

机构：

[1] Natl Taiwan Univ, Dept Chem Engn, Taipei 10617, Taiwan

[2] Rhodes Univ, Dept Biochem & Microbiol, Grahamstown, South Africa

[3] Natl Taiwan Univ Sci & Technol, Dept Chem Engn, Taipei 10607, Taiwan

[4] Tunghai Univ, Coll Engn, Taichung 40704, Taiwan

[5] Natl Taiwan Normal Univ, Coll Technol & Engn, Taipei 10610, Taiwan

来源：

JOURNAL OF THE TAIWAN INSTITUTE OF CHEMICAL ENGINEERS | 2019年 / 103卷

关键词：

Silver nanoparticles; HIV-1; protease; Inhibition; Cleavage; HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE-SITE; SUBSITE PREFERENCES; PROTEINASE; INHIBITORS; SUBSTRATE;

D O I：

10.1016/j.jtice.2019.07.019

中图分类号：

TQ [化学工业];

学科分类号：

0817 ;

摘要：

Use of silver nanoparticles (Ag NP's) as inhibitor for HIV-1 protease (PR) has practical interest. However, the interactions between the Ag NP's, HIV-1 PR, and the target peptides are not well demonstrated. This study experimentally revealed the interactions of the synthesized Ag NP's, HIV-1 PR, and five specific peptides with similar amino acid sequences to HIV's polyproteins. The Ag NP's can bind with either HIV-1 PR or the peptides. Incubating Ag NP's with peptide for 24 h can efficiently inhibit activity of HIV-1 PR. But HIV-1 PR would cleave peptides faster than the binding rate of Ag NP's and the peptides; therefore, late presence of Ag NP's would have no inhibition on the HIV-1 PR activity. (C) 2019 Taiwan Institute of Chemical Engineers. Published by Elsevier B.V. All rights reserved.

引用

页码：20 / 32

页数：13

共 28 条

[11] ACTIVE HUMAN IMMUNODEFICIENCY VIRUS PROTEASE IS REQUIRED FOR VIRAL INFECTIVITY [J].

KOHL, NE ;

EMINI, EA ;

SCHLEIF, WA ;

DAVIS, LJ ;

HEIMBACH, JC ;

DIXON, RAF ;

SCOLNICK, EM ;

SIGAL, IS .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (13) :4686-4690

[12] SUBSITE PREFERENCES OF THE ASPARTIC PROTEINASE FROM THE HUMAN-IMMUNODEFICIENCY-VIRUS, HIV-1 [J].

KONVALINKA, J ;

STROP, P ;

VELEK, J ;

CERNA, V ;

KOSTKA, V ;

PHYLIP, LH ;

RICHARDS, AD ;

DUNN, BM ;

KAY, J .

FEBS LETTERS, 1990, 268 (01) :35-38

[13]

Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P1, DOI [10.1186/1477-3155-8-1, 10.1186/1477-3155-8-15]

[14]

LEONARD CK, 1990, J BIOL CHEM, V265, P10373

[15] HIV protease inhibitors: a review of molecular selectivity and toxicity [J].

Lv, Zhengtong ;

Chu, Yuan ;

Wang, Yong .

HIV AIDS-RESEARCH AND PALLIATIVE CARE, 2015, 7 :95-104

[16] The active site of HIV-1 protease [J].

Mager, PP .

MEDICINAL RESEARCH REVIEWS, 2001, 21 (04) :348-353

[17] STRUCTURE OF COMPLEX OF SYNTHETIC HIV-1 PROTEASE WITH A SUBSTRATE-BASED INHIBITOR AT 2.3-A RESOLUTION [J].

MILLER, M ;

SCHNEIDER, J ;

SATHYANARAYANA, BK ;

TOTH, MV ;

MARSHALL, GR ;

CLAWSON, L ;

SELK, L ;

KENT, SBH ;

WLODAWER, A .

SCIENCE, 1989, 246 (4934) :1149-1152

[18]

Myers M, 1992, RETROVIRIDAE

[19] MUTATIONAL ANALYSIS OF A NATIVE SUBSTRATE OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 PROTEINASE [J].

PARTIN, K ;

KRAUSSLICH, HG ;

EHRLICH, L ;

WIMMER, E ;

CARTER, C .

JOURNAL OF VIROLOGY, 1990, 64 (08) :3938-3947

[20] Antiretroviral Therapy Current Drugs [J].

Pau, Alice K. ;

George, Jomy M. .

INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2014, 28 (03) :371-+

← 1 2 3 →